Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.260
-0.070 (-3.00%)
May 15, 2026, 4:00 PM EDT - Market closed
Lipocine Revenue
Lipocine had revenue of $119.40K in the quarter ending March 31, 2026, with 27.20% growth. This brings the company's revenue in the last twelve months to $2.00M, down -45.52% year-over-year. In the year 2025, Lipocine had annual revenue of $1.98M, down -82.35%.
Revenue (ttm)
$2.00M
Revenue Growth
-45.52%
P/S Ratio
9.06
Revenue / Employee
$143,015
Employees
14
Market Cap
18.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.98M | -9.22M | -82.35% |
| Dec 31, 2024 | 11.20M | 8.13M | 264.67% |
| Dec 31, 2023 | 3.07M | 2.57M | 514.16% |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
| Dec 31, 2018 | 428.03K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 7.71M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 7.06M |
| Traws Pharma | 2.73M |
| OSR Holdings | 2.63M |
| Longeveron | 1.22M |
| Exicure | 500.00K |
LPCN News
- 10 days ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 - PRNewsWire
- 4 weeks ago - Lipocine price target lowered to $6 from $11 at Alliance Global - TheFly
- 5 weeks ago - Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 5 weeks ago - Lipocine downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 6 weeks ago - Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial - TheFly
- 6 weeks ago - Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - PRNewsWire
- 2 months ago - Lipocine price target raised to $11 from $6.75 at Alliance Global - TheFly
- 2 months ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PRNewsWire